Skip to main content
PFSA
NASDAQ Industrial Applications And Services

Profusa Q2 Loss Widens to $8.8M; Going Concern Doubts Persist Amid Reverse Splits and G3 Option

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$12.96
Mkt Cap
$3.641M
52W Low
$3.223
52W High
$5,190.014
52W Position info
302% above low
Off High info
100% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

PFSA has more than doubled off its 52-week low of $3.223.

Summary

Profusa's Q2 2026 loss widened to $8.8M, cash fell to $0.7M, and going concern doubts persist. The 10-Q also details a 1-for-4 reverse split, workforce reduction, and new terms for the G3 Vision Labs option agreement.


Key Events · Earnings and Guidance · PFSA

  • Q2 Net Loss Widens to $8.8M

    Net loss for the three months ended June 30, 2026 was $8.755 million, up from $2.348 million in Q2 2025. Six-month loss reached $12.211 million.

  • Going Concern Doubts Persist

    Cash of $0.719 million and a working capital deficit of $27.3 million as of June 30, 2026. Management reiterates substantial doubt about the company's ability to continue as a going concern within one year.

  • Material Weaknesses Unremediated

    Internal control over financial reporting remains ineffective due to material weaknesses in segregation of duties, valuation of financial instruments, and technical accounting expertise.

  • Reverse Split and Workforce Reduction

    A 1-for-4 reverse stock split was effected on August 17, 2026. Workforce reduced from 11 to 5 employees to preserve liquidity.


Analysis · PFSA · Industrial Applications And Services

Profusa reported a net loss of $8.8 million for Q2 2026, bringing the six-month loss to $12.2 million. Cash has dwindled to $0.7 million against a working capital deficit of $27.3 million, and the company reiterates substantial doubt about its ability to continue as a going concern. The filing also discloses a 1-for-4 reverse stock split on August 17, 2026, a reduction in force from 11 to 5 employees, and the issuance of Series A Preferred Stock to settle $4.6 million of liabilities. The G3 Vision Labs option agreement, previously announced, is detailed with new terms: 50,280 common shares and 52,903.566 Series A Preferred Stock issued as consideration, with an additional 53,918.113 Series A Preferred Stock if the option is exercised, contingent on a $30 million financing. These events underscore severe liquidity strain and significant dilution risk.

At the time of this filing, PFSA was trading at $12.96 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $3.22 to $5,190.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PFSA - Latest Insights

PFSA
Aug 18, 2026, 5:25 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $23.81
Real-time Price: $13.31 info
Change: -$10.50 (-44%) info
Market Cap: $3.641M info
PFSA
Aug 13, 2026, 8:42 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8999
Real-time Price: $13.31 info
Change: Reverse Stock Split info
Market Cap: $3.641M info
PFSA
Jul 31, 2026, 5:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.860
Real-time Price: $13.31 info
Change: Reverse Stock Split info
Market Cap: $3.641M info
PFSA
Jul 31, 2026, 4:56 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.870
Real-time Price: $13.31 info
Change: Reverse Stock Split info
Market Cap: $3.641M info
PFSA
Jul 27, 2026, 6:08 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $13.31 info
Change: Reverse Stock Split info
Market Cap: $3.641M info